Drug Profile
Pelacarsen - Ionis Pharmaceuticals/Novartis
Alternative Names: AKCEA-APO(a)-LRx; IONIS-681257; IONIS-APO(a)-LRx; IONIS-APO-LRx; ISIS 681257; ISIS-APO(a)-LRx; ISIS-APOALRx; Pelacarsen sodium; TQJ 230Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Novartis; The Chinese University of Hong Kong
- Class Antihyperlipidaemics; Antisense oligonucleotides
- Mechanism of Action Apolipoprotein A inhibitors; Apolipoproteins A expression inhibitors; Gene silencing; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cardiovascular disorders; Hyperlipoproteinaemia
Most Recent Events
- 20 Feb 2024 Novartis Pharmaceuticals plans a phase III trial in Hyperlipoproteinaemia in USA (SC) in May 2024 (NCT06267560)
- 29 Sep 2023 Novartis Pharmaceuticals initiates a phase III trial in Hyperlipoproteinemia in Germany (SC) (NCT05900141)
- 12 Jun 2023 Novartis Pharmaceuticals plans a phase III trial in Hyperlipoproteinemia (SC) in August 2023 (NCT05900141)